Nature of the Business - Additional Information (Detail) - USD ($)		1 Months Ended			3 Months Ended
	Sep. 15, 2021	Mar. 31, 2022	Mar. 27, 2020	Jul. 12, 2019	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Apr. 03, 2017
Summary Of Significant Accounting Policies [Line Items]
Accumulated deficit		$ 546,224,000			$ 546,224,000		$ 546,092,000
Net loss from continuing operations					132,000	$ 696,000
Cash used in operating activities					354,000	$ 437,000
Cash, cash equivalents and marketable securities		14,300,000			$ 14,300,000
Celator Pharmaceuticals Inc [Member]
Summary Of Significant Accounting Policies [Line Items]
Cash payment received			$ 2,300,000
Reimbursement of expenses			200,000
Transaction expenses			$ 400,000
Asset Purchase Option Agreement [Member]
Summary Of Significant Accounting Policies [Line Items]
Gain related to option fee payment	$ 100,000
Asset Purchase Option Agreement [Member] | Pegascy SAS [Member]
Summary Of Significant Accounting Policies [Line Items]
Consideration receivable	500,000
Option fee	$ 100,000
Exercise period of option	24 months
Consideration received		500,000
Gain related to payment of consideration		$ 500,000
Ipsen [Member] | Asset Sale Agreement [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payments receivable								$ 450,000,000.0
Ipsen [Member] | First Line Treatment of Metastatic Adenocarcinoma of Pancreas [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payments receivable								225,000,000.0
Ipsen [Member] | After Failure of First Line Chemotherapy [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payments receivable								150,000,000.0
Ipsen [Member] | Additional Indication [Member]
Summary Of Significant Accounting Policies [Line Items]
Contingent milestone payments receivable								$ 75,000,000.0
14ner Sale [Member]
Summary Of Significant Accounting Policies [Line Items]
Upfront cash payment received				$ 3,500,000
14ner Sale [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				54,500,000
14ner Sale [Member] | Achievement of the Primary Endpoint in the First Registrational Clinical Study of Either MM-121 or MM-111 [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				3,000,000.0
14ner Sale [Member] | Achievement of Various Regulatory Approval and Reimbursement-Based Milestones in the United States, Europe and Japan [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				16,500,000
14ner Sale [Member] | Achievement Various Cumulative Worldwide Net Sales Targets Between $100.0 million and $300.0 million for MM-121 and MM-111 [Member] | Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Additional payments receivable on achievement of certain milestone events				35,000,000.0
Cumulative worldwide net sales target				300,000,000.0
14ner Sale [Member] | Achievement Various Cumulative Worldwide Net Sales Targets Between $100.0 million and $300.0 million for MM-121 and MM-111 [Member] | Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Cumulative worldwide net sales target				$ 100,000,000.0